评估青少年和年轻成人中按2剂方案接种MenB-FHbp的免疫原性、安全性和耐受性的3期研究
本3期研究评估10-25岁人群按0、6个月接种2剂MenB-FHbp的免疫原性和安全性,同时接种MenACWY-CRM。第2剂后针对各初选菌株的hSBA滴度≥4倍升高的受试者比例为67.4%至95.0%,复合应答率为74.3%。疫苗耐受性良好,研究者认为与接种相关的不良事件发生率为4.2%(44/1057),未发生与接种相关的严重不良事件。
要点
- 第2剂后各初选菌株hSBA滴度≥4倍升高比例为67.4%至95.0%,复合应答率为74.3%。
- 初选菌株应答对次选菌株应答具有高度预测性。
- 研究者认为与接种相关的不良事件发生率为4.2%(44/1057),无相关严重不良事件。
核心结论
- MenB-FHbp按0、6个月接种耐受性良好,并诱导针对不同B群菌株的保护性杀菌抗体应答。
- 研究结果进一步支持该人群中继续使用MenB-FHbp的2剂方案。
研究设计与样本
- 3期研究,10-25岁受试者在第0、6个月接种MenB-FHbp,并在第0个月接种四价脑膜炎球菌结合疫苗MenACWY-CRM。
- 共1057名受试者接种第1剂MenB-FHbp,946名受试者接种第2剂。
- 主要免疫原性终点包括第2剂后针对4株不同的、疫苗异源性B群初选测试菌株的hSBA滴度较基线≥4倍升高的受试者百分比,以及针对全部4株初选菌株合并的滴度≥定量下限(LLOQ;1:8或1:16)的复合应答。
主要发现
- 第2剂后针对各初选菌株的hSBA滴度≥4倍升高的受试者百分比范围为67.4%至95.0%,复合应答率为74.3%。
- 初选菌株应答对次选菌株应答具有高度预测性。
- 大多数反应原性事件为轻至中度,未导致退出研究。
- 研究者认为与接种相关的不良事件发生在4.2%(44/1057)的受试者中,未发生与接种相关的严重不良事件或新诊断的慢性疾病。
关键数值与推荐
- hSBA滴度≥1:4为公认的保护性相关指标。
- 主要免疫原性终点为第2剂后hSBA滴度较基线≥4倍升高及复合应答(滴度≥LLOQ;1:8或1:16)。
- 同时评估了针对另外10株疫苗异源性菌株的hSBA滴度≥LLOQ的受试者百分比。
临床怎么用
- 原文结论指出研究结果进一步支持该人群中继续使用MenB-FHbp的2剂方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The MenB-FHbp vaccine is licensed to prevent meningococcal serogroup B disease on either a 2-dose (0, 6 months) or 3-dose (0, 1-2, 6 months) series. This phase 3 study further assessed the immunogenicity and safety of the 2-dose MenB-FHbp schedule. METHODS: Subjects 10-25 years of age received MenB-FHbp (months 0, 6) and the quadrivalent meningococcal conjugate vaccine MenACWY-CRM (month 0). Primary immunogenicity endpoints included percentages of subjects achieving ≥ 4-fold increases from baseline in serum bactericidal antibody using human complement (hSBA) titers for 4 diverse, vaccine-heterologous primary serogroup B test strains and titers ≥ lower limit of quantitation (LLOQ; 1:8 or 1:16) for all 4 primary strains combined (composite response) after dose 2; a titer ≥ 1:4 is the accepted correlate of protection. Percentages of participants with hSBA titers ≥ LLOQ for 10 additional vaccine-heterologous strains were also assessed; positive predictive values of primary strain responses for secondary strain responses were determined. Safety was assessed. RESULTS: Overall, 1057 subjects received dose 1 and 946 received dose 2 of MenB-FHbp. Percentages of participants achieving ≥ 4-fold increases in hSBA titers against each primary strain after dose 2 ranged from 67.4% to 95.0% and the composite response was 74.3%. Primary strain responses were highly predictive of secondary strain responses. Most reactogenicity events were mild-to-moderate in severity and did not lead to withdrawal from the study. Adverse events (AEs) considered by the investigator to be related to vaccination occurred in 4.2% (44/1057) of subjects, and there were no serious AEs or newly diagnosed chronic medical conditions considered related to vaccination. CONCLUSIONS: MenB-FHbp administered at 0, 6 months was well tolerated and induced protective bactericidal antibody responses against diverse serogroup B strains. Findings provide further support for the continued use of MenB-FHbp on a 2-dose schedule in this population.
引用
- Drazan D, Czajka H, Maguire JD, et al. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults. Vaccine. 2021. PMID: 34961633. doi:10.1016/j.vaccine.2021.11.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。